ArticleFrontiers in oncology2026
Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) remains a leading cause of mortality in Canada, with outcomes often influenced by geographic disparities. While biomarker testing for RAS, BRAF, and microsatellite instability (MSI) is now standard for metastatic CRC (mCRC), it is unclear if these diagnostic advances are equitably accessible to rural populations. Methods: We conducted a retrospective, population-based cohort study of 818 patients diagnosed with stage IV CRC in Saskatchewan between 2017 and 2022. We evaluated differences based on patient residence (rural vs. urban) and diagnosing laboratory location (rural vs. urban) regarding clinical characteristics, biomarker status, treatment delays, and overall survival. Results: Rural patients had higher odds of right-sided tumors (aOR 1.76) and rectal tumors (aOR 1.52) compared to urban residents. Notably, RAS mutations were more frequently identified in rural patients (11.2% vs. 1.6%, p=0.021). While overall survival did not differ significantly by residency (median 250 vs. 270 days, p=0.774), patients diagnosed in rural laboratories experienced significantly longer delays from diagnosis to the initiation of chemotherapy (66.5 vs. 55 days, p=0.011) and a clinically relevant, though not statistically significant, delay in immunotherapy (77.5 vs. 65 days). Multivariable analysis confirmed that older age and poorer performance status were the primary predictors of mortality, rather than geography. Discussion: In Saskatchewan, stage IV CRC survival is comparable between rural and urban patients; however, the care pathway is hindered by systemic therapy delays linked to rural diagnostic laboratory locations. While survival rates are currently similar, the delays associated with rural laboratory workups represent an actionable target for improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.